KAZIA THERAPEUTICS LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours

Phase 1
Active, not recruiting
Conditions
Solid Tumor, Adult
Interventions
Drug: EVT801
First Posted Date
2021-11-10
Last Posted Date
2024-07-01
Lead Sponsor
Kazia Therapeutics Limited
Target Recruit Count
32
Registration Number
NCT05114668
Locations
🇫🇷

Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France

🇫🇷

Centre Léon Bérard, Lyon, France

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: [14C]-Paxalisib Capsule
First Posted Date
2021-08-19
Last Posted Date
2024-03-15
Lead Sponsor
Kazia Therapeutics Limited
Target Recruit Count
6
Registration Number
NCT05012670
Locations
🇬🇧

Quotient Sciences, Nottingham, United Kingdom

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

Phase 2
Completed
Conditions
Glioblastoma, Adult
Interventions
Drug: Paxalisib (GDC-0084)
First Posted Date
2018-05-11
Last Posted Date
2024-03-15
Lead Sponsor
Kazia Therapeutics Limited
Target Recruit Count
30
Registration Number
NCT03522298
Locations
🇺🇸

University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

First Posted Date
2016-09-16
Last Posted Date
2020-04-20
Lead Sponsor
Kazia Therapeutics Limited
Target Recruit Count
28
Registration Number
NCT02903771
Locations
🇦🇺

Westmead Adults Hospital, Westmead, New South Wales, Australia

🇦🇺

ICON Cancer Care, South Brisbane, Queensland, Australia

🇺🇸

Lifespan Cancer Institute, Rhode Island Hospital, Providence, Rhode Island, United States

and more 3 locations

Phenoxodiol in Treating Patients With Refractory Solid Tumors

First Posted Date
2003-01-27
Last Posted Date
2013-03-26
Lead Sponsor
Kazia Therapeutics Limited
Target Recruit Count
36
Registration Number
NCT00022295
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy